Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Dr Roy speaks with ecancer at EHA 23 about observed changes in blood stem cells over at different stages of development, from infancy to adulthood.
She describes how, starting from matched liver and bone marrow samples, changes in erythroid, myeloid and lymphoid progenitor cell populations can be charted, and differences between samples indicate a driver of differentiation in the microenvironment.
Dr Roy also spoke with ecancer about infantile leukaemia.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Predicting tumour mutations from pathology images may help increase personalised medicine utilisation
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
EHA 2024: Multiple myeloma roundup
Multiple myeloma in a resource constrained setting
OncoAlert Round Up for August 25th - 31st, 2023
Choosing Wisely in pathology
Choosing Wisely in radiology Tanzania